中关村(000931.SZ)公告称，公司全资子公司四环医药之控股子公司北京华素、山东华素、多多药业所 属部分药品入选《国家基本医疗保险、生育保险和工伤保险药品目录（2025年）》，共计34个在产产品 入选，包括新增生产销售产品硫酸鱼精蛋白注射液、复方胰酶散等。原进入《医保目录2024年》的产品 如富马酸比索洛尔片、盐酸贝尼地平片等继续入选。北京华素的"复方氯解磷定注射液"调出《医保目录 2025年》，多多药业的"盐酸氨溴索注射液"新增入选。入选产品未来的销售情况可能受到市场环境变化 等多重因素影响，不会对公司当期经营业绩产生重大影响。 ...

Core Viewpoint - Lijun Group (000513.SZ) announced that it has 194 products included in the National Medical Insurance Directory for 2025, which is expected to positively impact the company's operating performance in the future [1] Group 1: Product Inclusion - The group has 194 products in the National Medical Insurance Directory, including 92 Class A and 102 Class B products [1] - Injectable Aripiprazole microspheres have been included in the National Medical Insurance Directory for the first time through negotiations [1] - Injectable Triptorelin acetate microspheres have a new indication added, and Injectable Esomeprazole sodium has successfully renewed its contract [1] - No products from the group have exited the National Medical Insurance Directory [1] Group 2: Market Impact - The inclusion of these products in the National Medical Insurance Directory is expected to help expand the market and improve drug accessibility [1] - The new version of the National Medical Insurance Directory will be officially implemented on January 1, 2026, and is not expected to have a significant impact on the company's current operating performance [1]

Core Viewpoint - Sichuan Kelun Pharmaceutical Co., Ltd. has announced that five of its products have been included in the National Medical Insurance Directory for 2025, which is expected to enhance market expansion and sales scale for the company [1][2]. Group 1: Product Inclusion - Five products from the company and its subsidiaries have been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Directory for 2025 [1]. - The total sales of these products for the year 2024 are approximately 51.69 million yuan, and for the first half of 2025, the sales are approximately 309.75 million yuan, accounting for about 0.24% and 3.41% of the company's revenue during the respective periods [1]. Group 2: Impact on the Company - The inclusion of products in the 2025 Drug Directory is expected to facilitate the company's market network expansion and increase sales scale, although the exact impact on operating performance cannot be estimated at this time [2]. - The National Medical Insurance Directory will officially take effect on January 1, 2026, with further details on payment standards and reimbursement rules to be provided by relevant government departments [2].

Core Viewpoint - China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. has successfully negotiated to include its product Yiqi Qingfei Granules in the National Medical Insurance Directory (2025 version), which is expected to enhance the company's product portfolio in the respiratory field and strengthen its market position [1][3]. Product Information - Product Name: Yiqi Qingfei Granules - Drug Classification Code: ZA09G - Drug Type: Traditional Chinese Medicine (TCM) - Registration Category: TCM Class 3.2 - Dosage Form: Granules - Agreement Validity: January 1, 2026, to December 31, 2027 - Indications: Used for symptoms related to Qi and Yin deficiency, spleen deficiency, and dampness, including fatigue, shortness of breath, dry cough, and gastrointestinal discomfort [1][2]. Impact on the Company - Yiqi Qingfei Granules received its drug registration certificate from the National Medical Products Administration in January 2025 and is currently undergoing post-market academic promotion and sales activities. The inclusion in the National Medical Insurance Directory is expected to have a positive impact on the company's product layout in the respiratory field, although it is not anticipated to significantly affect short-term operating performance [3].

Core Viewpoint - Shandong Buchang Pharmaceutical Co., Ltd. successfully renewed the inclusion of its products Xuanfei Baidu Granules and Danhong Injection in the National Medical Insurance Directory for 2025, which is expected to positively impact the company's market position and sales performance [1][3]. Product Information - Xuanfei Baidu Granules are indicated for clearing lung heat and detoxifying, used for damp-heat obstructing the lungs, with symptoms including fever, cough, and shortness of breath [1]. - Danhong Injection is used for promoting blood circulation and alleviating pain, indicated for conditions such as chest pain and stroke, with symptoms including chest tightness and limb numbness [2]. Sales Impact - The National Medical Insurance Directory will be officially implemented on January 1, 2026, and the sales performance of the drugs may be influenced by various market factors, indicating a level of uncertainty [3].

公司及其控股子公司产品纳入《2025年药品目录》，将有利于促进公司产品拓展市场网络、提升销售规 模，预计对公司经营业绩的影响暂无法估计。国家医保目录（2025年）将于2026年1月1日起正式实施， 医保支付标准、医保报销细则等相关信息，需以国家医疗保障局等相关政府部门公示信息为准。 格隆汇12月8日丨科伦药业(002422.SZ)公布，国家医保局、人力资源社会保障部发布《关于印发 <国家 基本医疗> 保险、生育保险和工伤保险药品目录>以及 <商业健康保险创新药品目录> （2025年）的通 知》（ 医保发〔2025〕33号）。根据该通知，四川科伦药业股份有限公司及其控股子公司共计5个品种 纳入《国家基本医疗保险、生育保险和工伤保险药品目录（2025年）》。 ...

Core Insights - The announcement from Lijun Pharmaceutical (01513) indicates that a total of 194 products from the company have been included in the National Medical Insurance Catalog for 2025, with 92 classified as Category A and 102 as Category B [1] Group 1 - The inclusion of Lijun Pharmaceutical's products in the National Medical Insurance Catalog is significant for the company's market positioning and revenue potential [1] - Notably, the injectable Aripiprazole microspheres have been included in the catalog for the first time through negotiations, which may enhance its market access [1] - The injectable Triptorelin acetate microspheres have received an additional indication, potentially expanding its usage and sales opportunities [1] Group 2 - The injectable Esomeprazole sodium has successfully renewed its contract, ensuring continued reimbursement and market presence [1]

自願公告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性 亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致 的任何損失承擔任何責任。 本集團未有產品退出《國家醫保目錄》。本集团前述產品納入《國家醫保目錄》有助於後 續擴大市場及提高藥品可及性，預計未來將對本公司的經營業績產生積極影響。此版《國 家醫保目錄》將於2026年1月1日正式執行，預計不會對本公司当期經營業績產生重大影響。 2 醫保支付標準、醫保報銷細則等相關資訊需以國家醫保局等相關部門公示的資訊為准。公 司產品未來銷售情況受醫藥行業政策變動、市場環境變化等影響，具有一定的不確定性。 敬請廣大投資者審慎決策，注意投資風險。 公司產品納入國家醫保目錄 麗珠醫藥集團股份有限公司Livzon Pharmaceutical Group Inc.*（「本公司」，連同其附屬公 司，統稱「本集團」）自願作出，以告知本公司股東及潛在投資者本集團最新業務更新。 2025年12月7日，國家醫保局、人力資源社會保障部發佈了《國家基本醫療保險、生育保 險和工傷保險藥品目錄（2025年）》（醫保 ...

格隆汇12月8日丨海辰药业(300584.SZ)公布，国家医保局、人力资源社会保障部发布了《关于印发<国 家基本医疗保险、生育保险和工伤保险药品目录>以及<商业健康保险创新药品目录>（2025年）的通 知》（医保发〔2025〕33号），南京海辰药业股份有限公司注射用盐酸兰地洛尔（50mg）续约成功,注 射用盐酸兰地洛尔（150mg）首次纳入《国家基本医疗保险、工伤保险和生育保险药品目录（2025 年）》（简称"国家医保目录"）。 注射用盐酸兰地洛尔是新一代速效、超短效、高选择性β1受体阻滞剂，本品具有选择性高（其对β1受 体的阻滞作用约为β2受体的255倍，对β1受体的选择性为另一个超短效β受体阻滞药艾司洛尔的8倍）、 起效迅速（给药后1至6分钟起效）、半衰期短（约为4分钟）、停药后失效快、对心脏血流动力学影响 小、无明显负性肌力作用、对呼吸道影响最小等优点。兰地洛尔是《国家心力衰竭指南》（2023版）急 性心衰发作患者的心室率控制推荐用药；同时也是2024《急性心房颤动中国急诊管理指南》急性房颤的 推荐用药，兰地洛尔是欧洲2024ESC《心房颤动诊断和管理指南》控制心率的首选药物。公司该产品 2024年度实 ...

Core Viewpoint - The announcement by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security regarding the new National Medical Insurance Catalog (2025 version) includes the successful renewal of the company's环泊酚注射液 and the addition of安瑞克芬注射液, which is a significant development for the company and its product portfolio [1] Group 1 - The National Medical Insurance Catalog (2025 version) was officially released on December 7, 2025 [1] - The company has successfully renewed the listing of环泊酚注射液 and has added安瑞克芬注射液 to the new catalog [1] - 安瑞克芬注射液 is a self-developed high-selectivity peripheral kappa opioid receptor agonist and is the first non-narcotic prescription opioid analgesic approved for pain relief without being classified as a controlled substance [1] Group 2 - The company now has four class 1 innovative drugs included in the National Medical Insurance Catalog (2025 version), which are环泊酚注射液, 安瑞克芬注射液, 苯磺酸克利加巴林胶囊, and 考格列汀片 [1]